Daclatasvir coming to a pharmacy near you soon?

August 20, 2015:  Today we received news that another upcoming drug, daclatasvir (Daklinza™) from Bristol-Myers Squibb, has received a Notice of Compliance from Health Canada. It is already being considered for coverage by British Columbia's Pharmacare, though it has not yet been approved. This drug is unique in its potential to mix and match with other drugs in order to treat a variety of genotypes, including hard-to-treat genotype 3 (combined with Gilead

NOC granted to Canada’s first “interferon-free” combo, sofosbuvir/ledipasvir!

Canada's first "interferon-free combo" for hepatitis C, sofosbuvir+ledipasvir, now known by tradename HARVONI, was granted a "Notice of Compliance" (NOC) by Health Canada on Oct. 16, 2014. The NOC is basically an authorization to the combo's maker, Gilead Sciences, to market this treatment in the Canadian market. The pill, taken once a day for 8, 12, or 24 weeks (depending on condition of liver and previous treatment history), is only approved for use with

SOVALDI™ (sofosbuvir) approved by Health Canada

Sofosbuvir (trade name Sovaldi) has now been approved for use in Canada. There will still be many months before it is approved for coverage by your provincial Pharmacare plan. But meanwhile, if you are in great need of this drug but fear you cannot afford it, consider applying to Gilead Sciences compassionate care's Momentum Support Program™ or their Sovaldi Co-pay assistance program. See details in complete Gilead Sciences Press Release below. ###  HEALTH

GALEXOS™ (simeprevir) approved by Health Canada

Simeprevir (trade name Galexos) has now been approved for use in Canada. It is a once-daily pill which is taken along with ribavirin and pegylated interferon alfa to treat hepatitis C genotype 1 in a "triple therapy."  There will still be many months before it is approved for coverage by your provincial Pharmacare plan. See details in complete Janssen Inc. Press Release below. ### New Treatment for Hepatitis C Approved by Health Canada Priority Review Give